ABCA1 Exerts Tumor-Suppressor Function in Myeloproliferative Neoplasms

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Defective cholesterol efflux is linked to hematopoietic stem cell expansion and myeloid lineage bias, mimicking chronic myelomonocytic leukemia (CMML).
• ABCA1 plays a crucial role in cholesterol efflux and cellular homeostasis.

Purpose of the Study:

• To investigate the role of somatic mutations in ABCA1 in the pathogenesis of CMML.
• To elucidate the mechanisms by which ABCA1 mutations contribute to myeloid neoplasm progression.

Main Methods:

• Identification of ABCA1 mutations in CMML patients.
• In vitro proliferation assays of monocytic leukemia cell lines with ABCA1 mutations.
• In vivo studies using mouse models with ABCA1 inactivation or mutant expression alongside Tet2 loss.
• Analysis of signaling pathways (MAPK, JAK2) and metabolic reprogramming.
• Assessment of apolipoprotein A-1 transgene effects on myeloproliferation.

Main Results:

• Five somatic missense mutations in ABCA1 were identified in 26 CMML patients.
• ABCA1 mutations conferred a proliferative advantage to leukemia cell lines in vitro.
• ABCA1 inactivation or mutant expression, particularly with Tet2 loss, demonstrated a myelosuppressive function.
• ABCA1 mutations were found to increase IL-3Rβ signaling via MAPK and JAK2, leading to metabolic reprogramming and impairing tumor suppressor functions.
• Overexpression of apolipoprotein A-1 reduced myeloproliferation.

Conclusions:

• Somatic ABCA1 mutations subvert its anti-proliferative and cholesterol efflux functions, promoting myeloid neoplasm progression.
• Targeting cholesterol efflux pathways, such as by increasing high-density lipoprotein (HDL), offers a potential therapeutic strategy to restore normal hematopoiesis in CMML.